Immunogenicity of HIV-1(LAI) gp160 and env peptides in squirrel monkey Saimiri sciureus using alumine and experimental adjuvants

Clinical and Experimental Immunology

Volumn 106, Issue 3, 1996, Pages 434-441

  Perraut, R ^a,d   Chouteau, P ^a   Moog, C ^b   Bonnemains, B ^a   Kieny, M P ^c  

^a INSTITUT PASTEUR DE LA GUYANE   (French Guiana)

^b INSERM   (France)

^c TRANSGENE S A   (France)

^d INSTITUT PASTEUR DE DAKAR   (Senegal)

Author keywords

Adjuvants; GP 160; gp41 env peptide; Monkeys

Indexed keywords

GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; SYNTHETIC PEPTIDE; ALUMINUM POTASSIUM SULFATE; GLYCOPROTEIN 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MEMBRANE PROTEIN; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; VACCINATION; AMINO ACID SEQUENCE; ANIMAL; CEBIDAE; IMMUNOLOGY; MOLECULAR GENETICS;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ALUM COMPOUNDS; AMINO ACID SEQUENCE; ANIMALS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV-1; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; PEPTIDES; SAIMIRI;

EID: 0029658398     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-857.x     Document Type: Article

References (34)

1. Moore J, Lewis JK, Robinson J. Which gp160 vaccine? Nature 1993; 361:50.
2. Cooney EL, McElrath MJ, Corey L et al. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Immunology 1993; 90:1882-6.
3. Graham BS, Belshe RB, Clements ML et al. Vaccination of vaccinia-naive adults with human immunodeficienty virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J Infect Dis 1992; 166:244-52.
4. Graham BS, Matthews TJ, Belshe RB et al. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J Infect Dis 1993; 167:533-7.
5. Koff WC, Glass MJ. Future directions in HIV vaccine development. Aids Res Human Retroviruses 1992; 8:1313-5.
6. Bomford R. Adjuvants for viral vaccines. Medical Virology 1992; 2:169-74.
7. Capron A, Locht C, Fracchia GN. Safety and efficacy of new generation vaccines. Vaccine 1994; 12:667-9.
8. Kieny MP, Lathe R, Riviere Y, Dott K, Schmitt D, Girard M, Montagnier L, Lecocq JP. Improved antigenicity of the HIV env protein by cleavage site removal. Prot Eng 1988; 2:219-25.
9. Chong P, Sia C, Sydor M, Klein M. Identification of a potent synthetic HIV-1 immunogen compromising gag P24 tandem T- and B-cell epitopes. FEBS 1990; 264:231-4.
10. Katinger H, Muster T, Buchacher A et al. Results of preclinical screening and epitope mapping of human monoclonal antibodies against HIV-1. In: Girard M, Valette L, eds. Septième colloque des cent gardes: retroviruses of human AIDS and related animal disease. Paris: Fondation Mèrieux, 1992:299-303.
11. Purtscher M, Trkola A, Gruber G et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1994; 10:1651-8.
12. Klein M, Chong P, Matthews T, Zolla-Pazner S, James O, Gates G, Sia DY. Immunogenicity of synthetic HIV-1 T-B tandem epitopes. In: Girard M, Valette L, eds. Septième colloque des cent gardes: retroviruses of human AIDS and related animal disease. Paris: Fondation Mèrieux. 1992:169-75.
13. Allison AC, Byars NE. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J Immunol Methods 1986; 95:157-68.
14. Enders B, Hundt E, Bernhardt D, Schoriemmer HU, Weinmann E, Küpper HA. Comparative studies on the influence of different adjuvants on serum conversion after immunization with tetanus toxoid and recombinant malaria and viral antigens in mice and monkeys. In: Brown F, Chanock RM, Ginsburg HS, Lerner RA, eds. Vaccines 90: modern approaches to new vaccines including prevention of AIDS. New York: Cold Spring Harbour Press, 1990:29-45.
15. Gysin J, Pauillac S, Fandeur T. Characterization by anti-Ig monoclonal antibodies of protective and non-protective antibodies against asexual forms of Plasmodium falciparum in the Saimiri monkey. Ann Inst Pasteur/Immunol 1987; 138:829-44.
16. Ronco J, Dedieu JF, Marie FN, Pinter A, Kaczorek M, Girard M. High-titer HIV-1 neutralizing antibody response of rhesus macaques to gp160 and env peptides. Aids Res Human Retroviruses 1992; 8:1117-23.
17. Perraut R, Hundt E, Garraud O, Enders B, Gysin J. Comparison of the effects of adjuvants and adjuvant doses on the quantitative and qualitative antibody response to selected antigens in New World squirrel monkeys Saimiri sciureus. Vaccine 1993; 11:730-5.
18. Newman MJ, Wu JY, Coughlin RT, Murphy CI, Seals JR, Wyand MS, Kensil CR. Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in non human primates. Aids Res Human Retroviruses 1992; 8:1413-7.
19. Haigwood NL, Nara PL, Brooks E et al. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J Virol 1992; 66:172-82.
20. Bruck C, Thiriart C, Fabry L et al. HIV-1 envelope elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine 1994; 12:1141-8.
21. Perraut R, Chouteau P, Bourreau E, Bonnemains B, Garraud O. Assays for adjuvanticity of new formulations and of carrier proteins for inducing antibody responses to selected immunogens in the squirrel monkey Saimiri sciureus. Immunol Cell Biol 1994; 72:169 75.
22. Niedrig M, Gregersen JP, Fulz PN, Brker M, Hilfenhaus J, Mehdi S. Immune response of chimpanzees after immunization with the inactivated whole immunodeficiency virus (HIV-1). three different adjuvants and challenge. Vaccine 1993; 11:67-74.
23. Ahlers JD, Pendleton CD, Dunlop N, Minassian A, Nara PL, Berzofsky JA. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody response in mice of multiple MHC haplotypes after two immunizations. J Immunol 1993; 150:5647-65.
24. Jahaverian K, Langlois AJ, LaRosa GJ, Bolognesi DP, Herlihy WC, Putney SD, Matthews TJ. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 1990; 250:1590-3.
25. Fultz PN, Nara P, Barre-Sinoussi F, Chaput A, Greenberg ML, Kieny MP, Girard M. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 1992; 256:1687-9.
26. Bomford R, Stapleton M, Winsor S, McKinight A, Andronova T. The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants. Aids Res Human Retroviruses 1992; 8:1765-71.
27. Wu JY, Gardner BH, Murphy CI et al. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J Immunol 1992; 148:1519-25.
28. Defoort J, Nardelli B, Huang W, Tam JP. A rational design synthetic peptide vaccine with a built-in adjuvant. J Peptide Res 1992; 40:214-21.
29. +; cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. Proc Nat Acad Sci USA 1991; 88:9448 52.
30. Haynes BF, Arthur LO, Frost P et al. Conversion of an immunogenic Human Immunodeficiency Virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein. J Exp Med 1993; 177:717-27.
31. Cease KB, Berzofsky JA. Toward a vaccine for AIDS: the emergence of immunobiology-based vaccine development. Ann Rev Immunol 1994; 12:923-89.
32. Perraut R, Lussow AR, Gavoille S et al. Successful primate immunization with peptides conjugated to purified protein derivative or mycobacterial heat shock proteins in the absence of adjuvants. Clin Exp Immunol 1993; 93:382-6.
33. Sedlik C, Perraut R, Bonnemains B, Leclerc C. Antigens linked to synthetic microspheres induce immune response in primates in the absence of adjuvants. Immunobiology 1996; 195:105-18.
34. Garraud O. The squirrel monkey Saimiri sciureus: an experimental model for immunological studies on human pathogens. Med Sci Res 1992; 20:3-8.